AssetMark Inc
NTLA icon

AssetMark Inc’s Intellia Therapeutics NTLA Stock Holding History

AssetMark Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558 Hold
33
– – ﹤0.01% 3275
2026
Q1 		$423 Hold
33
– – ﹤0.01% 3207
2025
Q4 		$297 Sell
33
-13
-28% -$179 ﹤0.01% 3198
2025
Q3 		$794 Buy
+46
New +$567 ﹤0.01% 2834
2022
Q1 		– Sell
-30
Closed -$4K – 1684
2021
Q4 		$4K Buy
+30
New +$3.76K ﹤0.01% 1274

Other funds holding NTLA

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AssetMark Inc's NTLA Position: Q2 2026 in Review

AssetMark Inc held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 33 shares worth $558. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

AssetMark Inc first reported a position in NTLA in Q4 2021 and has held it in 5 quarters since. The position peaked at $4K in Q4 2021. 112 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • AssetMark Inc held 33 shares of Intellia Therapeutics worth $558 as of Q2 2026.
  • AssetMark Inc left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3275 holding.
  • AssetMark Inc first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • AssetMark Inc's Intellia Therapeutics position peaked at $4K in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.